Longeveron® to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Rhea-AI Summary

Longeveron (NASDAQ: LGVN), a clinical stage regenerative medicine biotech company, will present at the H.C. Wainwright 27th Annual Global Investment Conference in New York City. The presentation is scheduled for Monday, September 8, 2025, from 4:00 to 4:30 p.m. ET.

The company, which focuses on developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, will make the presentation available via webcast. Investors can access the webcast through the "Events and Presentations" section of Longeveron's website, with replay access available for 180 days following the conference.

MIAMI, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will participate in the H.C. Wainwright 27^th Annual Global Investment Conference taking place September 8-10, 2025 in New York City.

Details for the Company’s presentation:
	Date:	Monday, September 8, 2025
	Time:	4:00 – 4:30 p.m. ET

The webcast for this conference presentation may be accessed at the “Events and Presentations” section of the Company’s website. A replay of the webcast will be available on the Longeveron website for 180 days following the conference.

About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is laromestrocel (Lomecel-B™), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Laromestrocel has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing four pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, Pediatric Dilated Cardiomyopathy (DCM) and Aging-related Frailty. Laromestrocel development programs have received five distinct and important FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.

Investor and Media Contact:
Derek Cole
Investor Relations Advisory Solutions 
derek.cole@iradvisory.com

FAQ

When is Longeveron (LGVN) presenting at the H.C. Wainwright Conference 2025?

Longeveron will present on Monday, September 8, 2025, from 4:00 to 4:30 p.m. ET at the conference in New York City.

How can investors access Longeveron's (LGVN) H.C. Wainwright conference presentation?

Investors can access the presentation webcast through the 'Events and Presentations' section of Longeveron's website, with replay available for 180 days after the conference.

What type of company is Longeveron (LGVN)?

Longeveron is a clinical stage regenerative medicine biotechnology company that develops cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions.

Where is the H.C. Wainwright Global Investment Conference 2025 being held?

The H.C. Wainwright 27th Annual Global Investment Conference is being held in New York City from September 8-10, 2025.